Identification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-associated DNA methylation patterns.
Trivedi, Malav S, Oltra, Elisa, Sarria, Leonor et al. · PloS one · 2018 · DOI
Quick Summary
Researchers studied chemical tags on DNA (called methylation) in people with ME/CFS compared to healthy people. While the overall amount of these tags was similar between groups, they found specific locations on thousands of genes where the tags differed. Many of these differences were in genes involved in immune system function, which aligns with what doctors already know about ME/CFS affecting immunity.
Why It Matters
This is the first comprehensive genome-wide epigenetic study of ME/CFS using advanced microarray technology, providing evidence that immune dysregulation in ME/CFS may have an epigenetic basis. If validated in larger cohorts, these methylation patterns could potentially serve as objective diagnostic biomarkers, addressing a critical unmet need in ME/CFS clinical practice.
Observed Findings
Global DNA methylation levels were similar between ME/CFS cases and healthy controls
17,296 differentially methylated CpG sites identified across 6,368 genes in ME/CFS cases
307 differentially methylated promoter regions detected in ME/CFS cases
Differentially methylated genes involved in immune-related and cell-signaling pathways
Findings validated in two geographically distant cohorts using pyrosequencing
Inferred Conclusions
Epigenetic dysregulation at specific CpG sites may contribute to ME/CFS pathobiology
Immune system dysfunction in ME/CFS may involve altered DNA methylation patterns
Methylation biomarkers could potentially be developed for diagnostic purposes with further validation
Epigenetic changes may help explain the dysregulation of immune function documented in previous ME/CFS research
Remaining Questions
Do these methylation patterns appear before ME/CFS develops, or only after illness onset?
Are specific methylation signatures associated with particular ME/CFS symptom subgroups or disease severity?
What This Study Does Not Prove
This study does not prove that methylation changes cause ME/CFS—it only shows associations in a small sample. It cannot establish whether these epigenetic changes are primary drivers of disease or secondary consequences of the illness. Larger, prospective studies are needed to validate these findings and determine their clinical utility.